Related Experiment Video
Updated: May 27, 2026

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas
Published on: November 11, 2025
Pancreatic peptides in young and elderly Zucker type 2 diabetic fatty rats
Frank Christopher Howarth1, Mey Khalfan Ahmed Ali Al Kitbi, Rasheed Shaul Hameed
1Department of Physiology, Faculty of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates. chris.howarth@uaeu.ac.ae
Context:
The global prevalence of diabetes mellitus, and in particular type 2 diabetes mellitus is increasing at an alarming rate. Risk factors for development of diabetes include obesity and advancing age.
Objectives:
The distribution of insulin, glucagon, somatostatin and pancreatic polypeptide in the pancreatic islets has been investigated in young and elderly type 2 Zucker diabetic fatty (ZDF) rats and age-matched Zucker lean (ZL) controls.
Methods:
Experiments were performed in male animals aged either 9-13 weeks or 30-34 weeks. Immunohistochemistry was used to label insulin, glucagon, somatostatin and pancreatic polypeptide in islet cells.
Results:
The percentage of insulin-positive cells was unaltered in young but decreased in elderly ZDF (35.5 ± 2.5%) rats compared to ZL controls (57.9 ± 1.8%). The percentage of glucagon-positive cells was increased in young ZDF (58.7 ± 3.4%) compared to ZL controls (23.4 ± 2.1%). However, in elderly rats the percentage of glucagon-positive cells declined in ZDF rats and was no longer different from ZL controls. The percentage of somatostatin-positive cells was unaltered in young and elderly ZDF rats compared to ZL controls. The percentage of pancreatic polypeptide-positive cells was unaltered in young but increased in elderly ZDF (22.0 ± 2.5%) rats compared to ZL controls (13.8 ± 1.8%).
Conclusions:
The distribution of pancreatic hormones is altered to varying extents in the ZDF rat and during the normal aging process.
Related Concept Videos
Chronic Pancreatitis II: Pathophysiology
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes II: Pathophysiology
